Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 5.00 (0.29%)
Spread: 0.50 (0.029%)
Open: 1,733.00
High: 1,739.50
Low: 1,724.50
Prev. Close: 1,728.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

London midday: Corporate earnings weigh on stocks ahead of Fed minutes

Tue, 20th Aug 2013 11:41

A number of poorly-received results from blue-chip companies and ongoing concerns about the future of US stimulus weighed heavily on markets on Tuesday morning, dragging the FTSE 100 to levels not seen in over six weeks.London's benchmark index reached an intraday low of around 6,400 early on before trimming losses slightly by midday; still, the last time it closed lower was on July 5th when it finished the day at 6,375.52.Rising US bond yields and speculation about an impending tapering of asset purchases by the Federal Reserve have hit market sentiment over recent weeks. Investors are now choosing to adopt a cautious approach ahead of the minutes of the Federal Open Market Committee (FOMC) meeting due out tomorrow."We're seeing a lot more risk aversion in the markets now, with Asian indices plummeting over night and European stocks following suit this morning. With very little data out over night and again today, investors are clearly preparing themselves ahead of the Fed minutes which will be released on Wednesday," said Market Analyst Craig Erlam from Alpari.While Erlam isn't expecting any surprises from the minutes - given that a potential decision to taper still remains dependent on incoming economic data - he said: "That has never stopped the markets panicking in the past and doesn't look like stopping them now. The markets hate uncertainty."FTSE 100: Wood Group, CRH, miners drop sharplyOil and gas services company Wood Group slumped this morning after scaling back its full-year EBITA growth guidance for its engineering division from 15% to "10-15%", reflecting some project delays and further weakening in Canada. EBITA in the first half was up 18.6% year-on-year.CRH also fell sharply after swinging to a loss for the half-year period. The building materials firm reported a loss before tax of €71m, down from €102m the year before, while sales fell 3.0% to €8.01bn.Mining stocks were also out of favour today as results from BHP Billiton and Glencore Xstrata failed to impress. BHP said lower commodity prices wiped $8.9bn off its underlying earnings which plunged 22.4% in the year to the end of June, while Glencore Xstrata was forced to write down $7.7bn in assets as it reported a 9.0% drop in first-half adjusted EBITDA.Even housebuilder Persimmon fell into the red by midday despite a strong jump early on. The company said that first-half profits jumped 38% and its order book was running 21% ahead of last year as the government's 'Help to Buy' scheme boosted demand.Defensive stocks were in demand today as relatively 'riskier' assets (such as those in the resources sectors) were sold off. Telecom giant BT, utilities peers National Grid and United Utilities and pharmaceutical giant GlaxoSmithKline were all making gains this morning.Meggitt, the engineering group working in the aerospace, defence and energy markets, was slightly higher after Investec upgraded the stock from 'add' to 'buy', saying it still sees further upside even after a strong performance this year.FTSE 100 - RisersCompass Group (CPG) 869.50p +1.40%BT Group (BT.A) 326.30p +1.27%GlaxoSmithKline (GSK) 1,659.00p +0.85%National Grid (NG.) 739.50p +0.82%Meggitt (MGGT) 536.50p +0.75%Aggreko (AGK) 1,680.00p +0.60%British American Tobacco (BATS) 3,410.00p +0.49%Tate & Lyle (TATE) 824.50p +0.49%Vodafone Group (VOD) 190.70p +0.45%British Land Co (BLND) 570.50p +0.44%FTSE 100 - FallersWood Group (John) (WG.) 831.50p -7.92%CRH (CRH) 1,363.00p -4.42%Vedanta Resources (VED) 1,153.00p -3.92%Prudential (PRU) 1,146.00p -3.37%Glencore Xstrata (GLEN) 292.25p -3.21%Standard Chartered (STAN) 1,477.00p -2.89%Lloyds Banking Group (LLOY) 73.08p -2.56%BHP Billiton (BLT) 1,907.50p -2.48%GKN (GKN) 332.10p -2.24%G4S (GFS) 241.50p -1.91%FTSE 250 - RisersFisher (James) & Sons (FSJ) 1,054.00p +5.56%Ladbrokes (LAD) 200.00p +4.44%Crest Nicholson Holdings (CRST) 331.00p +2.41%Hikma Pharmaceuticals (HIK) 1,087.00p +1.40%NMC Health (NMC) 334.50p +1.36%Barr (A.G.) (BAG) 565.00p +1.35%Britvic (BVIC) 562.50p +1.35%Keller Group (KLR) 1,056.00p +1.25%Centamin (DI) (CEY) 37.48p +0.75%Lancashire Holdings Limited (LRE) 750.00p +0.74%FTSE 250 - FallersBrewin Dolphin Holdings (BRW) 259.00p -5.99%Computacenter (CCC) 510.00p -5.38%Hochschild Mining (HOC) 222.10p -4.64%Evraz (EVR) 117.50p -4.55%Ashmore Group (ASHM) 338.40p -4.05%Fenner (FENR) 345.50p -3.81%Inchcape (INCH) 610.50p -3.63%Perform Group (PER) 530.00p -3.55%Utilico Emerging Markets Ltd (DI) (UEM) 167.50p -3.29%Menzies(John) (MNZS) 735.50p -3.16%BC
More News
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more
21 Feb 2024 09:47

GSK reports encouraging results for ViiV's Cabenuva HIV treatment

(Alliance News) - GSK PLC on Wednesday said that its majority-owned company ViiV Healthcare had received positive interim data from ongoing trials of its injectable HIV treatment.

Read more
21 Feb 2024 07:22

GSK's ViiV sees success in latest HIV treatment trial

(Sharecast News) - GSK's specialist HIV unit ViiV Healthcare, which it owns in partnership with Pfizer and Shionogi, unveiled promising findings from the 'LATITUDE' phase three trial of its long-acting injectable HIV treatment Cabenuva on Wednesday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.